---
schema_version: "secwatch.filing_event.v1"
accession: "0001178670-25-000008"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:49:36.959125+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alnylam reports preliminary FY2024 net product revenues of $1.65B (+33% YoY); guides FY2025 $2.05-2.25B

## Summary
- Q4 2024 net product revenues ~$451M; FY2024 ~$1,646M, representing 33% annual growth.
- 2025 combined net product revenue guidance of $2.05B-$2.25B, 31% growth at mid-point vs 2024.
- TTR franchise (ONPATTRO/AMVUTTRA): FY2024 ~$1,223M; 2025 guidance $1.6B-$1.725B (36% growth).
- Rare franchise (GIVLAARI/OXLUMO): FY2024 ~$423M; 2025 guidance $450M-$525M (15% growth).
- Company expects 2025 non-GAAP operating income profitability; vutrisiran PDUFA date March 23, 2025.

## SEC filing metadata
- accession: 0001178670-25-000008
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/0001178670-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000008/alny-20250112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178670-25-000008
- JSON: https://secwatch.observer/filing/0001178670-25-000008.json
- Plain text: https://secwatch.observer/filing/0001178670-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.